GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
539
c/survodutide·posted 3 months ago by u/nora_ramos

[Meta] the dual agonist rule is doing its job and people should stop complaining

Caution Slow Clap ×4

Been lurking in c/dosinglogs for about 15 months and finally have something worth posting.

Short version: week 62, 1.7mg, and glucagon is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 39 threads, and the answers split roughly down the middle.

What I actually want to know is whether the people saying it does not matter have measured it, or whether it is just repeated confidently. Happy to be told I am overthinking this — I probably am — but I would rather overthink it now than at week 68.

623 up / 84 down88% upvoted24 commentsid 1wxv2810 Apr 2026

24 comments

23 in this archive, depth 5

best — the order this archive was captured in

u/rafael_sjoberg56 points·3 months ago

hepatic fat and survodutide are the story

replysharereportpermalink
[removed]40 points·3 months ago

[removed by moderator]

replysharereportpermalink
u/deleted_my_history22 points·3 months ago

The confident tone is doing a lot of work that the evidence is not.

replysharereportpermalink
u/border_paperwork-35 points·3 months ago

phase 19 data is interesting, phase 38 will be different

replysharereportpermalink
u/jarno_adeyemi1 point·3 months ago

not approved, descriptive posts only

replysharereportpermalink
u/injection_site_iris18 points·3 months ago

the UK here. Waited 16 months on a list, gave up, went private, and the total cost was roughly what I expected.

replysharereportpermalink
u/nora_ramosOP7 points·3 months ago

rodent dual agonist is investigation only

replysharereportpermalink
u/elin_tamm29 points·3 months ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/zeynep_villalobos20 points·3 months ago

phase 12 data is interesting, phase 13 will be different

replysharereportpermalink
u/renzo_asante22 points·3 months ago

Respectfully this is a sample of one presented as a finding.

replysharereportpermalink
u/nora_ramosOP12 points·3 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/nora_ramos3 points·3 months ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
u/elin_ferrari3 points·3 months ago

rodent dual agonist is investigation only

replysharereportpermalink
u/cesar_ivaturi1 point·3 months ago

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

replysharereportpermalink
u/isabela_nilsen15 points·3 months ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/julia_mensa6 points·3 months ago

hepatic fat and survodutide are the story

replysharereportpermalink
u/trialwatch_theoMOD11 points·3 months ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/georgi_adebayo13 points·3 months ago·edited

Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.

replysharereportpermalink
u/injection_site_iris0 points·3 months ago

phase 23 data is interesting, phase 14 will be different

replysharereportpermalink
u/slow_logbook_notes301 point·3 months ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/nora_ramos0 points·3 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/hub_opssite staff0 points·3 months ago

Small correction: the trial was 5 weeks, not 37. Does not change your point but people will quote it.

replysharereportpermalink
load more comments (1) →
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.